Herbalife Nutrition Ltd vs Tilray Brands Inc — how do they compare? Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Herbalife Nutrition Ltd is far larger — about 2.5× Tilray Brands Inc's market cap, and Herbalife Nutrition Ltd is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Tilray Brands Inc for 31 Days on average.
| HLF | TLRY | |
|---|---|---|
Market Cap | $1.34B | $530.54M |
Volume | 1,589,457 | 9,099,075 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $21.00 |
52-Week Low | $7.75 | $3.57 |
Typical Hold Time | 43 Days | 31 Days |
Enterprise Value | $3.18B | $684.46M |
Signals from Pluang's Aura AI — not financial advice
Herbalife (HLF) trades at $12.86, up 1.62% on the day, with a bullish technical signal and a consensus analyst price target of $19.00 implying significant upside. The company reported Q2 2026 EPS of $0.51, missing expectations, but reaffirmed full-year 2026 guidance. Financials show a net income margin of 3.16% for 2025, with a low P/E of 8.22 and P/S of 0.26, suggesting potential undervaluation. Recent news includes a $250 million share repurchase authorization and a planned CEO transition effective October 31, 2026.
The outlook for HLF is cautiously optimistic, with valuation metrics and analyst sentiment supporting a bullish case, but risks include recent earnings misses, high debt levels, and ongoing leadership changes. The stock presents a value opportunity if the company can execute on its growth and margin expansion plans while managing its leverage.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →